Home » Topics » Disease categories and therapies » Dermatologic

Dermatologic
RSS

Propecia recommended for approval for hair loss in men

Dec. 9, 1997

Preclinical profile of Novartis' dermatology candidate

Dec. 9, 1997

Promising results reported from pilot trial of Repel

Dec. 9, 1997

New melanogenesis inhibitor isolated from actinomycete

Dec. 1, 1997

Novel retinoids from Roche

Dec. 1, 1997

MedImmune seeks FDA approval for psoriasis trials with MEDI-507

Nov. 28, 1997

Clinical efficacy of naltrexone demonstrated in patients with cholestatic pruritus

Nov. 27, 1997

New histamine antagonists described for dermatological indications

Nov. 21, 1997

Phase II begins for psoriasis vaccine

Nov. 20, 1997

Rogaine Extra Strength approved by FDA as OTC

Nov. 19, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.